Glossary CKD Chronic kidney disease CVD Cardiovascular disease FDA Food and Drug Administration GLP-1 Glucagon-like peptide-1 GLP-1s Glucagon-like peptide-1 receptor agonists HF Heart failure MASH Metabolic dysfunction-associated steatohepatitis OA Osteoarthritis OSA Obstructive sleep apnea PAD Peripheral arterial disease SC Subcutaneous T2DM Type 2 diabetes mellitus U.S
Specifically, outcomes were grouped and presented by clinical domain, individual population, and intervention type, as reported in the original meta-analyses
Possible side effects include: Mild injection site irritation Occasional dizziness or headaches Nausea Systemic effects are less common
External resources American College of Lifestyle Medicine Joint Advisory on Nutritional Priorities During GLP-1 Therapy Nutritional Deficiencies and Muscle Loss in GLP-1 Users: Retrospective Observational Study Frontiers in Nutrition: Investigating Nutrient Intake During GLP-1 Receptor Agonist Use In case I do not see you, good afternoon, good evening, and good night
Average reply time during business hours: under 5 minutes.